Drugs Archives - McAlinden Research Partners

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals

Obesity Drugs Trail Surgical Methods in Total Weight Loss and Sustainability, Insurers Lean Toward Latter

New study data indicates that the popularity of GLP-1 injectables from Eli Lilly and Novo Nordisk continues to be overshadowed…

McAlinden Research PartnersJune 17, 2024

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Pfizer and Moderna Look to Put COVID Bust Behind Them, Add New Drug Development to Pipelines

Several drugmakers whose sales boomed on COVID-19 vaccines and related products in 2021 and 2022 have now been embroiled in a hangover…

McAlinden Research PartnersOctober 18, 2023

★ Daily Intelligence Briefings (DIBs)Markets Politics & Policy

Psilocybin Decriminalized in Second US State, Trial Data Shows Sustained Effect of Psychedelic Treatment

Successful approval of Proposition 122 in Colorado made it the second state in the US to decriminalize hallucinogenic mushrooms like psilocybin. Clinics…

McAlinden Research PartnersNovember 17, 2022

★ Daily Intelligence Briefings (DIBs)Politics & Policy Services

Biden’s Cannabis Pardons Revive Decriminalization Debate in Lead-Up to Key Midterm Elections

A wave of pardons from President Biden will be felt by thousands across the US who have been previously convicted…

McAlinden Research PartnersOctober 13, 2022

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare

Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics

The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…

McAlinden Research PartnersJanuary 4, 2022

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Markets

Biotech, Pharma Cash Piles set to Drive Dealmaking and Buyback Activity in 2022

Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…

McAlinden Research PartnersDecember 22, 2021

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Markets

AI Promises to Accelerate Drug Discovery, Streamline Biotech Breakthroughs

AI is transforming industries across every sector of the economy. Biotech and pharma are now experiencing a boom in AI initiatives…

McAlinden Research PartnersJuly 27, 2021

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Politics & Policy

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

Encouraging results from recent clinical trials testing the efficacy of using psychedelics like arketamine, LSD, and psilocybin to treat mental…

McAlinden Research PartnersMay 24, 2021

★ Daily Intelligence Briefings (DIBs)Commodities Politics & Policy Services

Cannabis Legalization Could be the Remedy for States Drained by COVID

Support for the legalization of Cannabis for recreational use has become increasingly popular among the majority of Americans. Now, tax…

McAlinden Research PartnersJune 24, 2020

Drugs

Obesity Drugs Trail Surgical Methods in Total Weight Loss and Sustainability, Insurers Lean Toward Latter

Pfizer and Moderna Look to Put COVID Bust Behind Them, Add New Drug Development to Pipelines

Psilocybin Decriminalized in Second US State, Trial Data Shows Sustained Effect of Psychedelic Treatment

Biden’s Cannabis Pardons Revive Decriminalization Debate in Lead-Up to Key Midterm Elections

Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics

Biotech, Pharma Cash Piles set to Drive Dealmaking and Buyback Activity in 2022

AI Promises to Accelerate Drug Discovery, Streamline Biotech Breakthroughs

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

Cannabis Legalization Could be the Remedy for States Drained by COVID

Joe Mac’s Viewpoint

The Newest Market Insights

Browse by Sector

About Us

Terms & Privacy